Moderna, Inc. (MRNA)
| Previous close | 125.59 |
| Open | 125.00 |
| Bid | 121.67 x 100 |
| Ask | 122.58 x 100 |
| Day's range | 122.04 - 126.40 |
| 52-week range | 62.55 - 142.79 |
| Volume | |
| Avg. volume | 3,922,682 |
| Market cap | 46.748B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the nomination of its first lead candidate under the collaboration with Moderna, Inc. (Nasdaq: MRNA). This first lead candidate will target an antigen present on a solid tumor with significant unmet medical need. This strategic collaboration brings together Carisma's chimeric antigen receptor macrophage
- Business Wire
Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer
RAHWAY, N.J. & CAMBRIDGE, Mass., December 11, 2023--Merck and Moderna Initiate INTerpath-002 Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA for Certain Types of Resected NSCLC
- PR Newswire
Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics
Flagship Pioneering, the bioplatform innovation company, today unveiled Quotient Therapeutics, a company pioneering somatic genomics, the study of genetic variation at the cellular level, to discover therapeutics informed by new links between genes and disease. Flagship has made an initial commitment of $50 million to advance development of the company's platform following two years of development at Flagship Labs and pursue a pipeline of medicines across a wide range of therapeutic areas and mo
